title: Clinical benefit of eribulin (Halaven®) in the treatment of advanced soft tissue sarcoma patients and the novel anti-tumor mechanisms.
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Koyama
authors.forename: Shigeru
authors.initials: S
authors.lastname: Taniguchi
authors.forename: Kotaro
authors.initials: K
authors.lastname: Kodama
authors.forename: Osamu
authors.initials: O
authors.lastname: Tohyama
authors.forename: Hiroki
authors.initials: H
authors.lastname: Hasegawa
authors.forename: Taro
authors.initials: T
authors.lastname: Semba
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002454:Cell Differentiation / Q000187:drug effects; D002986:Clinical Trials as Topic; D005663:Furans / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy*; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides